Company: IMNN
Filing Date: 2025-05-12
Form Type: 10-Q
Source: 0001641172-25-009572
Chunk: 2

Company: Imunon, Inc.
Filing Date: 2025-05-12
Form: 10-Q
Item: Part I, Item 1
Chunk 2
---
 

    Net loss 
    $(4,102,495) 
    $(4,929,525)

    Weighted average shares outstanding 

    Basic and diluted 
     14,558,186  
     9,399,831 

    Net loss per common share 

    Basic and diluted 
    $(0.28) 
    $(0.52)

See accompanying notes to the unaudited condensed
consolidated financial statements.

3

IMUNON, INC.

CONDENSED CONSOLIDATED

STATEMENTS OF COMPREHENSIVE LOSS

(Unaudited)

    2025  
    2024 

    For the Three Months Ended March 31, 

    2025  
    2024 
  
    Other comprehensive loss 

    Changes in: 

    Realized and unrealized gains on available for sale securities, net 
    $-  
    $72,305 

    Net loss 
     (4,102,495) 
     (4,929,525)

    Total comprehensive loss 
    $(4,102,495) 
    $(4,857,220)

See accompanying notes to the unaudited condensed
consolidated financial statements.

4

IMUNON, INC.

CONDENSED CONSOLIDATED

STATEMENTS OF CASH FLOWS

(Unaudited)

    2025  
    2024 

    For the Three Months Ended March 31, 

    2025  
    2024 
  
    Cash flows from operating activities: 

    Net loss 
    $(4,102,495) 
    $(4,929,525)

    Adjustments to reconcile net loss to net cash used in operating activities: 

    Depreciation 
     66,681  
     70,301 
  
    Amortization of right-of-use assets 
     131,246  
     108,009 
  
    Realized losses, net, on investment securities 
     -  
     73,466 
  
    Stock-based compensation 
     204,533  
     (30,679)
  
    Realization of deferred income tax asset 
     -  
     1,280,385 
  
    Net changes in: 

    Advances, deposits, and other current assets 
     (84,008) 
     259,561